Form 4: Unity Biotechnology CEO Granted Stock Options
SEC Form 4 Filing
Anirvan Ghosh, CEO of Unity Biotechnology, was granted stock options for 450,000 shares on January 22, 2025.
Summary
- An SEC Form 4 filing reveals that Anirvan Ghosh, the Chief Executive Officer of Unity Biotechnology, Inc. (UBX), was granted stock options.
- The transaction occurred on January 22, 2025.
- Ghosh received options to purchase 450,000 shares of Unity Biotechnology's common stock at an exercise price of $2.09 per share.
- One third of the shares subject to the option vest on December 31, 2025 and the remaining shares subject to the option vest in 24 successive, equal monthly installments thereafter on each monthly anniversary of December 31, 2025 until fully vested on December 31, 2027, subject to continued service.
Sentiment
Score: 7
Explanation: The document indicates a standard executive compensation practice, which is generally viewed neutrally to positively as it aligns management with shareholder interests. The vesting schedule promotes long-term commitment.
Positives
- The granting of stock options to the CEO aligns his interests with those of the shareholders, incentivizing him to increase the company's value.
- The vesting schedule encourages long-term commitment from the CEO.
Industry Context
Stock options are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align management's interests with those of shareholders.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the biotechnology industry.
- Companies like Amgen, Gilead Sciences, and Biogen also utilize stock options as part of their executive compensation plans.
- The vesting schedule and exercise price are typical for such grants, designed to incentivize long-term performance.
Stakeholder Impact
- Shareholders may view the stock option grant positively as it incentivizes the CEO to increase the company's value.
- Employees may see this as a sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 01/22/2025 | Date of the stock option grant. |
| 12/31/2025 | Date when one-third of the shares begin to vest. |
| 12/31/2027 | Date when all shares are fully vested, subject to continued service. |
| 01/21/2035 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.